GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Korro Bio Inc (NAS:KRRO) » Definitions » ROC (Joel Greenblatt) %

Korro Bio (Korro Bio) ROC (Joel Greenblatt) % : -224.74% (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Korro Bio ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Korro Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -224.74%.

The historical rank and industry rank for Korro Bio's ROC (Joel Greenblatt) % or its related term are showing as below:

KRRO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -620.02   Med: -497.05   Max: -264.06
Current: -264.06

During the past 3 years, Korro Bio's highest ROC (Joel Greenblatt) % was -264.06%. The lowest was -620.02%. And the median was -497.05%.

KRRO's ROC (Joel Greenblatt) % is ranked better than
53.85% of 1467 companies
in the Biotechnology industry
Industry Median: -333.95 vs KRRO: -264.06

Korro Bio's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Korro Bio ROC (Joel Greenblatt) % Historical Data

The historical data trend for Korro Bio's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Korro Bio ROC (Joel Greenblatt) % Chart

Korro Bio Annual Data
Trend Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
-497.05 -620.02 -309.05

Korro Bio Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
ROC (Joel Greenblatt) % - -750.68 -541.55 -279.98 -224.74

Competitive Comparison of Korro Bio's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Korro Bio's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Korro Bio's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Korro Bio's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Korro Bio's ROC (Joel Greenblatt) % falls into.



Korro Bio ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 1.963) - (4.372 + 0 + 2.046)
=-4.455

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 6.578) - (8.754 + 0 + 8.738)
=-10.914

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Korro Bio for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-94.56/( ( (41.334 + max(-4.455, 0)) + (42.815 + max(-10.914, 0)) )/ 2 )
=-94.56/( ( 41.334 + 42.815 )/ 2 )
=-94.56/42.0745
=-224.74 %

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Korro Bio  (NAS:KRRO) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Korro Bio ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Korro Bio's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Korro Bio (Korro Bio) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
One Kendall Square, Suite 6-401, Building 600-700, Cambridge, MA, USA, 02139
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Executives
David L. Lucchino director, officer: President and CEO C/O FREQUENCY THERAPEUTICS, INC., 19 PRESIDENTIAL WAY, 2ND FLOOR, WOBURN MA 01801
Rick Yang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Edward T Mathers 10 percent owner C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Nessan Bermingham director 890 WINTER STREET, WALTHAM MA 02451
Atlas Venture Associates Xi, Llc 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
New Enterprise Associates 17, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 17, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea 17 Gp, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Atlas Venture Fund Xi, L.p. 10 percent owner 400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Opportunity Fund Ii, L.p. 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Llc 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Atlas Venture Associates Opportunity Ii, Lp 10 percent owner 300 TECHNOLOGY SQUARE, 8TH FLOOR, CAMBRIDGE MA 02139
Steve Colletti officer: Chief Scientific Officer C/O KORRO BIO, INC., ONE KENDALL SQUARE, BUILDING 600-700, CAMBRIDGE MA 02139
Shelby J. Walker officer: See Remarks C/O KORRO BIO, INC., ONE KENDALL SQUARE, BUILDING 600-700, CAMBRIDGE MA 02139

Korro Bio (Korro Bio) Headlines

From GuruFocus

Korro Announces $70 Million Private Placement

By Marketwired 04-18-2024